Candid Co.
-73%
est. 2Y upside i
Rank
#3530
Sector
Medical Equipment Manufacturing
Est. Liquidity
~4Y
Data Quality
Data: LowGiven the 68% revenue decline and stale valuation from 2020, the expected upside over 2 years is -73% with high risk.
Last updated: July 19, 2026
Bull case assumes exit multiple holds at 5x on flat $50M revenue, yielding $250M exit. After 25% dilution from anticipated raise, net return -25%. Unlikely given revenue decline.
Base case assumes exit multiple compresses to 3x, exit value $150M. After 25% dilution, net return -65%. Preference overhang severe at 59%.
Bear case assumes exit multiple falls to 2x, exit $100M below total funding $148M, so common stock recovers near zero. Net return -100% after dilution.
Preference Stack Risk
severeFunding Intensity
59%Total funding $148M against estimated valuation $250M creates 59% preference overhang, severely diluting common equity in any exit below $250M.
Dilution Risk
highWith no recent funding and revenue declining, a dilutive raise within 2 years is highly probable, reducing common ownership by ~25%.
Secondary Liquidity
noneNo secondary trading available; no recent transactions.
Questions to Ask at the Interview
Strategic questions based on Candid Co.'s data — designed to show you've done your homework.
- 1
“How will Candid regain revenue growth after the 68% decline?”
- 2
“What is the path to profitability given the pivot to B2B?”
- 3
“How does the equity package compare to a cash-heavy offer given the liquidation preference overhang?”
Community
Valuation Sentiment
Our model estimates -73% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.